Jennifer H. R. Kenty

Jennifer H. R. Kenty

Auto-generated profile, based on publicly available information

Jennifer H. R. Kenty

Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EREdwin A. Rosado-Olivieri
Edwin A. Rosado-Olivieri
KAKendall Anderson
Kendall Anderson
JKJennifer H. Kenty
Jennifer H. Kenty
DMDouglas A. Melton
Douglas A. Melton
Stem cell-derived insulin-producing beta cells (SC-β) offer an inexhaustible supply of functional β cells for cell replacement therapies and disease modeling for diabetes. While successful directed differentiation protocols for this cell type have been described, the mechanisms controlling its differentiation and function are not fully understood. Here we report that the Hippo pathway controls the proliferation and specification of pancreatic progenitors into the endocrine lineage. Downregulation of YAP, an effector of the pathway, enhances endocrine progenitor differentiation and the generation of SC-β cells with improved insulin secretion. A chemical inhibitor of YAP acts as an inducer of endocrine differentiation and reduces the presence of proliferative progenitor cells. Conversely, sustained activation of YAP results in impaired differentiation, blunted glucose-stimulated insulin secretion, and increased proliferation of SC-β cells. Together these results support a role for YAP in controlling the self-renewal and differentiation balance of pancreatic progenitors and limiting endocrine differentiation in vitro.

29 August 2019 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
AGAaron L. Glieberman
Aaron L. Glieberman
BPBenjamin D. Pope
Benjamin D. Pope
JZJohn F. Zimmerman
John F. Zimmerman
Qihan LiuQihan Liu
Qihan Liu
JFJohn P. Ferrier
John P. Ferrier
KPKevin Kit Parker
Kevin Kit Parker
A device engineered from scalable materials for automated islet loading, synchronized stimulus delivery, and continuous on-chip insulin detection.

7 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
QPQuinn P Peterson
Quinn P Peterson
AVAdrian Veres
Adrian Veres
LCLihua Chen
Lihua Chen
MSMichael Q. Slama
Michael Q. Slama
JKJennifer H. R. Kenty
Jennifer H. R. Kenty
DMDouglas A. Melton
Douglas A. Melton
The generation of pancreatic cell types from renewable cell sources holds promise for cell replacement therapies for diabetes. Although most effort has focused on generating pancreatic beta cells, considerable evidence indicates that glucagon secreting alpha cells are critically involved in disease progression and proper glucose control. Here we report on the generation of stem cell-derived human pancreatic alpha (SC-alpha) cells from pluripotent stem cells via a transient pre-alpha cell intermediate. These pre-alpha cells exhibit a transcriptional profile similar to mature alpha cells and although they produce proinsulin protein, they do not secrete significant amounts of processed insulin. Compound screening identified a protein kinase c activator that promotes maturation of pre-alpha cells into SC-alpha cells. The resulting SC-alpha cells do not express insulin, share an ultrastructure similar to cadaveric alpha cells, express and secrete glucagon in response to glucose and some glucagon secretagogues, and elevate blood glucose upon transplantation in mice.